Browse the evidence

Weight loss and fat mass loss through lifestyle and pharmacologic interventions improve metabolic and inflammatory markers, suggesting a link to decreased breast cancer risk.

Practitioners should encourage weight loss and fat mass reduction as strategies to lower breast cancer risk.

bMVPA performed in the afternoon is associated with a greater reduction in HbA1c compared to inactive individuals, with a reduction of -0.22%.

Practitioners may consider recommending afternoon physical activity to improve glycemic control in patients with type 2 diabetes.

Therapeutic strategies that promote significant and sustained weight loss (~10% of total body weight) are among the most efficient for treating NASH and T2D.

Weight loss interventions should be prioritized in managing NASH and T2D.

The risk of major adverse cardiovascular events (MACE) decreases after approximately 10% of weight loss in patients who underwent metabolic surgery.

Practitioners should aim for at least 10% weight loss in surgical patients to reduce cardiovascular risk.

A threshold of approximately 5% weight loss is associated with reduced all-cause mortality in patients who underwent metabolic surgery.

Practitioners should encourage at least 5% weight loss in surgical patients to improve survival rates.

Fasting lipid parameters are generally improved by low-carbohydrate diets.

Practitioners should consider the quality of fats in low-carbohydrate diets when assessing lipid improvements.

Metabolic surgery is more effective than lifestyle or medical management in achieving glycemic control, sustained weight loss, and reducing diabetes comorbidities.

Practitioners should consider metabolic surgery as a treatment option for patients with type 2 diabetes who do not respond to lifestyle or medical management.

Low-carbohydrate, high-fat diets demonstrate benefits in terms of obesity, diabetes, dyslipidemia, and metabolic derangement.

Practitioners may consider recommending low-carbohydrate, high-fat diets for improving metabolic health.

Obesity surgery is indicated for patients with BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with obesity-related comorbidities.

Practitioners should consider obesity surgery for patients meeting these BMI criteria and with relevant comorbidities.

Metabolic surgery for type 2 diabetes is indicated for patients with BMI ≥ 30 kg/m² and as a primary indication for those with BMI ≥ 40 kg/m².

Practitioners should evaluate metabolic surgery for diabetic patients who meet these BMI criteria.

Limiting saturated fatty acids intake to <10% of total caloric intake in obesity and <7% in hypercholesterolemia is recommended.

Practitioners should advise patients to limit saturated fat intake according to these guidelines.

Daily dietary fiber intake should reach a level of 25-40 g.

Encourage patients to increase their dietary fiber intake to meet these levels.

Bariatric surgery leads to a higher remission rate for type 2 diabetes mellitus than non-surgical treatment.

Bariatric surgery should be considered for patients with type 2 diabetes who are not achieving remission through non-surgical methods.

INV-202 exhibited significant reductions in waist circumference and BMI (P ≤ 0.03).

INV-202 may help reduce waist circumference and BMI in this population.

Older ICU patients seldom meet the recommended protein intake.

Increase protein provision for older ICU patients to meet recommendations.

Individualized FATmax training reduced body fat% in older women with type 2 diabetes (p<0.001).

Practitioners can consider FATmax training as an effective method for reducing body fat in older women with type 2 diabetes.

Individualized FATmax training improved insulin resistance in older women with type 2 diabetes (p<0.001).

FATmax training may be recommended to improve insulin sensitivity in this population.

Clinical data supporting the use of various FDA-approved medications for weight loss are presented.

Practitioners can rely on clinical data when prescribing FDA-approved weight loss medications.

For trials with a mean BMI ≥35, LDL cholesterol decreased by 7 mg/dL on a low-carbohydrate diet.

Practitioners should note that low-carbohydrate diets may lower LDL cholesterol in individuals with high BMI.

High total protein intake is associated with low CVD morbidity (RR 0.88, 95% CI 0.82-0.94).

Encouraging higher protein intake may reduce the risk of cardiovascular disease.

Greater volume load (VL) plays a primary role for hypertrophy, regardless of interset rest interval.

Emphasizing volume load in training can enhance muscle growth, irrespective of rest intervals.

>10% weight loss is strongly associated with major macrovascular events (HR, 1.75; 95% CI, 1.26-2.44) in patients with type 2 diabetes.

>10% weight loss in patients with type 2 diabetes should prompt further cardiovascular risk assessment.

Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.

Practitioners should emphasize lifestyle changes in addition to pharmacotherapy for optimal management.

Lifestyle interventions should be the first line of defense against the development of type 2 diabetes (T2D).

Practitioners should prioritize lifestyle modifications in T2D prevention strategies.